The new version also delivers new functionality for the analysis of kinetic binding assays for small and large molecules, as well as a host of new automation features.
High-speed data analysis enables the scale-up of mechanism-of-action and kinetic assays for in-depth hit and lead characterization
BASEL, SWITZERLAND (PRWEB) JANUARY 31, 2018
Genedata, a leading provider of advanced software solutions for R&D, today announced the release of Genedata Screener® 15, featuring extended support of large-scale mechanistic analyses. The new version also delivers new functionality for the analysis of kinetic binding assays for small and large molecules, as well as a host of new automation features. All these capabilities plus a new web-accessible version of Screener will be demonstrated at SLAS2018 (Genedata Booth #1141; Feb 3-7, San Diego Convention Center).
The Screener platform is relied on by leading pharmaceutical companies, CROs, and academic research institutions around the world for processing, standardizing and integrating experimental data from all types of screens. Eliminating the need for spreadsheets and manual data handling, Genedata Screener 15 new automation features save more than 80% of a scientist’s time, while enabling experimental throughput to scale-up by a factor of 100 or more. Furthermore, improved support for large-molecule assays is made possible through new instrument integrations and analyses for surface plasmon resonance (SPR) and bio-layer interferometry (BLI) experiments.
Mechanistic Analysis on the Rise
Scaling up capacity for mechanism-of-action (MoA) studies is a strategic initiative for most pharma companies in order to use the results from these studies to improve compound selection early in the hit-to-lead process. Typically, such experiments, which include time-resolved cross-titrations to elucidate a compound’s mechanism, are very difficult to analyze. Now, Screener 15 enables scientists to process mechanistic screening data for hundreds of compounds in seconds, review preliminary results in a few minutes, and with a single mouse-click share final results with peers. This high level of automation significantly reduces time and resources typically devoted to the data analysis of such experiments, and removes a bottleneck for the scale-up of mechanistic assays. Inherently flexible, Screener for Mechanistic Analysis creates a balance between automation and interactivity to give scientists in-depth diagnostics, re¬view, re-processing options, and high quality results. Developed in close collaboration with leaders in the pharmaceutical industry, Screener for Mechanistic Analysis ensures consistent and reliable processing of biophysical and mechanistic assays in high throughput.
Large-Molecule Screening, New Workflow Automation & A New Web-version
Since its first release in 2002, the Screener platform has continually evolved to streamline data workflows and improve data quality. Screener 15 adds to this evolution by streamlining the BLI and SPR data analysis workflows for the discovery of large-molecule therapeutics. This improved support also applies to small molecules and is complemented with new instrument integrations with Creoptix WAVE, Pall ForteBio Octet, and Sierra Sensors MASS. Furthermore, Screener 15 delivers:
- New automation capabilities for real-time tracking of screening experiments using user-defined QC criteria; automated sessions that connect laboratory automation with automated data analysis; and integration with HighRes Biosolutions Cellario for real-time analysis of data from HighRes robotic systems.
- A new web-accessible version of the Screener platform opens up the system for access from anywhere at any time and brings 15 years of pharmaceutical know-how into an intuitive experience. Both standard client and web-based versions are available to users as separate menu items and fully interchangeable in Screener.
“With Genedata Screener 15, we not only extend the platform’s capabilities with mechanistic analysis, we continue to push the envelope on workflow automation and instrument integrations – all of which enable our customers to increase the efficiency of their screening operations,” noted Dr. Othmar Pfannes, CEO of Genedata. “We remain committed to our collaborative approach, working with the global leaders in biopharmaceutical R&D to generate the next generation of therapies as efficiently as possible”
SLAS2018 Editorial Note
Large molecule analysis and mechanistic analysis will be showcased at Genedata SLAS tutorials:
- “Genedata Screener Provides an Efficient Solution for Analysis of Bio-Layer Interferometry Assay,” February 5; 2:00 pm; Room 2.
- “A New Software Solution for Scalable and Streamlined Processing of High-throughput Data from Mechanistic Screening,” February 6; 9:30am – 10:15am; Room 5A.
About Genedata
Genedata transforms data into intelligence with innovative software solutions and domain-specific consulting services that automate complex, large-scale experimental processes and enable organizations to maximize the ROI from their R&D. Founded in 1997, Genedata is headquartered in Switzerland and has offices in Germany, the UK, Japan, and the US. http://www.genedata.com.
Follow Genedata on LinkedIn
Disclaimer
The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company’s products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
All product and service names mentioned are the trademarks of their respective companies.
